Company Filing History:
Years Active: 2002
Title: Innovations of Wesley Kwon Mung Chong
Introduction
Wesley Kwon Mung Chong is a notable inventor based in Encinitas, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target protein kinases. His work is aimed at addressing critical health issues, including cancer and other diseases associated with unwanted cell proliferation.
Latest Patents
Wesley Kwon Mung Chong holds a patent for "Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use." This patent describes compounds with heterocyclic-hydroxyimino-fluorene nuclei that modulate and inhibit the activity of specific protein kinases. These compounds and their pharmaceutical compositions are capable of mediating tyrosine kinase signal transduction, which is essential for modulating unwanted cell proliferation. The invention also encompasses therapeutic and prophylactic uses of these pharmaceutical compositions, particularly in treating cancer and other conditions linked to unwanted angiogenesis and cellular proliferation, such as diabetic retinopathy, glaucoma, rheumatoid arthritis, and psoriasis.
Career Highlights
Wesley Kwon Mung Chong is currently associated with Agouron Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His expertise in developing targeted therapies has positioned him as a valuable asset in the fight against various diseases.
Collaborations
Wesley collaborates with Rohit Kumar Duvadie, contributing to the advancement of their shared goals in pharmaceutical research and development.
Conclusion
Wesley Kwon Mung Chong's innovative work in the field of pharmaceuticals highlights his commitment to improving health outcomes through targeted therapies. His contributions are paving the way for new treatments that address significant medical challenges.